• 1
    Dinney CPN, Babkowski MA, Perrotte P et al. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol 1998; 160: 128590
  • 2
    Jakse G, Loidl W, Seeber G, Hofstadter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol 1987; 137: 393
  • 3
    Serretta V, Piazza S, Pavone C, Piazza B, Pavone-Macaluso M. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder. Urology 1996; 47: 6471
  • 4
    Vikram B, Malamud S, Silverman P, Hecht H, Grabstald H. A pilot study of chemotherapy alternating with twice-a-day accelerated radiation therapy as an alternative to cystectomy in muscle infiltrating (stages T2 and T3) cancer of the bladder: preliminary results. J Urol 1994; 151: 6024
  • 5
    Stockle M, Jacobi GH, Hohenfellner R. Importance of early cystectomy for the prognosis of cancer of bladder. J Urol 1988; 94: 4014
  • 6
    Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987; 138: 11623
  • 7
    Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Calabuig C. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term follow up of a prospective study. J Urol 1998; 159: 958
  • 8
    Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997; 80: 7625
  • 9
    Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner D. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 1990; 144: 6415
  • 10
    Pagano F, Bassi P, Galetti TP et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145: 4550
  • 11
    Herr HW, Klein EA, Rogatko A. Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival. Eur Urol 1991; 19: 97100
  • 12
    Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 14358DOI: 10.1097/00000478-199812000-00001
  • 13
    Brawn PN. The relationship between non-invasive papillary lesion and invasive bladder carcinoma. Cancer 1984; 54: 6203
  • 14
    Kaye KW, Lange PH. Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol 1981; 128: 313
  • 15
    Thrasher JB, Frazier HA, Robertson JE, Paulson DF. Does a stage pT0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer? J Urol 1994; 152: 3936
  • 16
    Soloway MS, Lopez AE, Patel J, Lu Y. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994; 73: 192631
  • 17
    Frazier HA, Roberston JE, Dodge RK, Pauslon DF. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993; 71: 39934001
  • 18
    Cookson MS, Herr H, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-years outcome. J Urol 1997; 158: 627
  • 19
    Kurth K, Tunn U, Ay R et al. and Members of the European Organization for Research and Treatment of Cancer Genitourinary Group. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for research and treatment of cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 1997; 158: 37884
  • 20
    Simoneau AR, Jones PA. Bladder cancer: the molecular progression to invasive disease. World J Urol 1994; 12: 8995
  • 21
    Popov Z, Hoznek A, Colombel M et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997; 80: 14728
  • 22
    Ick K, Schultz M, Stout P, Fan K. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment. Urology 1997; 49: 5416
  • 23
    Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 125964
  • 24
    Llopis J, Alcaraz A, Ribal MJ et al. p53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol 2000; 28: 64453


  1. Authors

R. Yiou, MD, Resident.

J.-J. Patard, MD, Assistant Professor of Urology.

H. Benhard, MD, Urologist attending.

C.-C. Abbou, MD, Professor of Urology.

D.K. Chopin, MD, Professor of Urology.


carcinoma in situ.